NovaDigm Therapeutics Presents Positive Safety and Immunogenicity Data in a Second Phase 1 Study for NDV-3 Vaccine
5/7/2012 9:52:42 AM
GRAND FORKS, N.D.--(BUSINESS WIRE)--NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study. The presentation was made at the 15th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Baltimore, MD. NDV-3 is a vaccine being developed for the prevention and treatment of diseases caused by Candida and Staphylococcus aureus (including methicillin-resistant S. aureus, or MRSA). NDV-3 contains recombinant Als3, a surface adhesin/invasin from Candida albicans, which is the first vaccine antigen to demonstrate preclinical “cross-kingdom” protective efficacy against both fungal and bacterial pathogens. Results from the new study demonstrated that a single dose of NDV-3 with or without alum adjuvant was safe, well-tolerated and induced strong antibody and T-cell immune responses.